261 related articles for article (PubMed ID: 34696274)
1. Resistance Mechanisms Influencing Oncolytic Virotherapy, a Systematic Analysis.
Bhatt DK; Chammas R; Daemen T
Vaccines (Basel); 2021 Oct; 9(10):. PubMed ID: 34696274
[TBL] [Abstract][Full Text] [Related]
2. Interferon-Mediated Tumor Resistance to Oncolytic Virotherapy.
Ebrahimi S; Ghorbani E; Khazaei M; Avan A; Ryzhikov M; Azadmanesh K; Hassanian SM
J Cell Biochem; 2017 Aug; 118(8):1994-1999. PubMed ID: 28135008
[TBL] [Abstract][Full Text] [Related]
3. Enhanced susceptibility of cancer cells to oncolytic rhabdo-virotherapy by expression of Nodamura virus protein B2 as a suppressor of RNA interference.
Bastin D; Aitken AS; Pelin A; Pikor LA; Crupi MJF; Huh MS; Bourgeois-Daigneault MC; Bell JC; Ilkow CS
J Immunother Cancer; 2018 Jun; 6(1):62. PubMed ID: 29921327
[TBL] [Abstract][Full Text] [Related]
4. JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models.
Patel MR; Dash A; Jacobson BA; Ji Y; Baumann D; Ismail K; Kratzke RA
Cancer Gene Ther; 2019 Nov; 26(11-12):411-418. PubMed ID: 30622322
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic targeting of androgen-sensitive prostate tumor by the respiratory syncytial virus (RSV): consequences of deficient interferon-dependent antiviral defense.
Echchgadda I; Chang TH; Sabbah A; Bakri I; Ikeno Y; Hubbard GB; Chatterjee B; Bose S
BMC Cancer; 2011 Jan; 11():43. PubMed ID: 21276246
[TBL] [Abstract][Full Text] [Related]
6. Mitophagy enhances oncolytic measles virus replication by mitigating DDX58/RIG-I-like receptor signaling.
Xia M; Gonzalez P; Li C; Meng G; Jiang A; Wang H; Gao Q; Debatin KM; Beltinger C; Wei J
J Virol; 2014 May; 88(9):5152-64. PubMed ID: 24574393
[TBL] [Abstract][Full Text] [Related]
7. Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy.
Ghonime MG; Cassady KA
Cancer Immunol Res; 2018 Dec; 6(12):1499-1510. PubMed ID: 30352799
[TBL] [Abstract][Full Text] [Related]
8. Virus, Oncolytic Virus and Human Prostate Cancer.
Liu GB; Zhao L; Zhang L; Zhao KN
Curr Cancer Drug Targets; 2017; 17(6):522-533. PubMed ID: 27993115
[TBL] [Abstract][Full Text] [Related]
9. Stem Cell-Based Cell Carrier for Targeted Oncolytic Virotherapy: Translational Opportunity and Open Questions.
Kim J; Hall RR; Lesniak MS; Ahmed AU
Viruses; 2015 Nov; 7(12):6200-17. PubMed ID: 26633462
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic virotherapy.
Cervantes-García D; Ortiz-López R; Mayek-Pérez N; Rojas-Martínez A
Ann Hepatol; 2008; 7(1):34-45. PubMed ID: 18376364
[TBL] [Abstract][Full Text] [Related]
11. VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells.
Currier MA; Eshun FK; Sholl A; Chernoguz A; Crawford K; Divanovic S; Boon L; Goins WF; Frischer JS; Collins MH; Leddon JL; Baird WH; Haseley A; Streby KA; Wang PY; Hendrickson BW; Brekken RA; Kaur B; Hildeman D; Cripe TP
Mol Ther; 2013 May; 21(5):1014-23. PubMed ID: 23481323
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulation in Oncolytic Measles Virotherapy.
Dietz L; Engeland CE
Methods Mol Biol; 2020; 2058():111-126. PubMed ID: 31486034
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic polio virotherapy of cancer.
Brown MC; Dobrikova EY; Dobrikov MI; Walton RW; Gemberling SL; Nair SK; Desjardins A; Sampson JH; Friedman HS; Friedman AH; Tyler DS; Bigner DD; Gromeier M
Cancer; 2014 Nov; 120(21):3277-86. PubMed ID: 24939611
[TBL] [Abstract][Full Text] [Related]
14. Novel oncolytic viral therapies in patients with thoracic malignancies.
Ahmad Z; Kratzke RA
Oncolytic Virother; 2017; 6():1-9. PubMed ID: 28053943
[TBL] [Abstract][Full Text] [Related]
15. SIRT1 Modulates the Sensitivity of Prostate Cancer Cells to Vesicular Stomatitis Virus Oncolysis.
Muscolini M; Castiello L; Palermo E; Zevini A; Ferrari M; Olagnier D; Hiscott J
J Virol; 2019 Aug; 93(15):. PubMed ID: 31092575
[TBL] [Abstract][Full Text] [Related]
16. Spatial and temporal epithelial ovarian cancer cell heterogeneity impacts Maraba virus oncolytic potential.
Tong JG; Valdes YR; Sivapragasam M; Barrett JW; Bell JC; Stojdl D; DiMattia GE; Shepherd TG
BMC Cancer; 2017 Aug; 17(1):594. PubMed ID: 28854921
[TBL] [Abstract][Full Text] [Related]
17. Autonomous parvoviruses neither stimulate nor are inhibited by the type I interferon response in human normal or cancer cells.
Paglino JC; Andres W; van den Pol AN
J Virol; 2014 May; 88(9):4932-42. PubMed ID: 24554651
[TBL] [Abstract][Full Text] [Related]
18. Modifying oncolytic virotherapy to overcome the barrier of the hypoxic tumor microenvironment. Where do we stand?
Shayan S; Arashkia A; Azadmanesh K
Cancer Cell Int; 2022 Nov; 22(1):370. PubMed ID: 36424577
[TBL] [Abstract][Full Text] [Related]
19. Kinase inhibitors with viral oncolysis: Unmasking pharmacoviral approaches for cancer therapy.
Gilchrist VH; Jémus-Gonzalez E; Said A; Alain T
Cytokine Growth Factor Rev; 2020 Dec; 56():83-93. PubMed ID: 32690442
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic potency of oncolytic virotherapy in breast cancer targeting, current status and perspective.
Ebrahimi S; Ghorbani E; Shafiee M; Ryzhikov M; Hassanian SM; Azadmanesh K
J Cell Biochem; 2019 Mar; 120(3):2801-2809. PubMed ID: 30260014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
